摘要
BackgroundOsimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy.MethodsIn this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non-small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed [500 mg per square meter of body-surface area] plus either cisplatin [75 mg per square meter] or carboplatin [pharmacologically guided dose]) or to receive osimertinib monotherapy (80 mg once daily). The primary end point was investigator-assessed progression-free survival. Response and safety were also assessed.ResultsA total of 557 patients underwent randomization. Investigator-assessed progression-free survival was significantly longer in the osimertinib-chemotherapy group than in the osimertinib group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.79; P<0.001). At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib-chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free. Progression-free survival as assessed according to blinded independent central review was consistent with the primary analysis (hazard ratio, 0.62; 95% CI, 0.48 to 0.80). An objective (complete or partial) response was observed in 83% of the patients in the osimertinib-chemotherapy group and in 76% of those in the osimertinib group; the median response duration was 24.0 months (95% CI, 20.9 to 27.8) and 15.3 months (95% CI, 12.7 to 19.4), respectively. The incidence of grade 3 or higher adverse events from any cause was higher with the combination than with monotherapy - a finding driven by known chemotherapy-related adverse events. The safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents.ConclusionsFirst-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC.
学科与关键词
- Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)Janne, P.; Planchard, D.; Cheng, Y.; Yang, J. C. -H.; Yanagitani, N.; Kim, S. -W.; Sugawara, S.; Yu, Y.; Fan, Y.; Geater, S. L.; Laktionov, K.; Lee, C. K.; Valdivieso, N.; Ahmed, S.; Maurel, J. -M.; Andrasina, I.; Goldman, J.; Ghiorghiu, D.; Kulkarni, D.; Huang, X.; Kobayashi, K.被引 1
- First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohortCheng, Y.; Yu, Y.; Fan, Y.; Jiang, L.; Wu, L.; Hu, J.; Wang, J.; Yao, W.; Han, Z.; Yao, Y.; Fang, J.; Sun, M.; Wang, Q.; Pan, Y.; Wu, R.; Liu, J.; Liu, Y.; Kulkarni, D.; Huang, X.; Janne, P. A.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trialLv, Chao; Fang, Wentao; Wu, Nan; Jiao, Wenjie; Xu, Shidong; Ma, Haitao; Wang, Jia; Wang, Rui; Ji, Chunyu; Li, Shaolei; Wang, Yuzhao; Yan, Shi; Lu, Fangliang; Pei, Yuquan; Liu, Yinan; Yang, Yue*Lung Cancer, 2023, 178: 151-156.被引 10
